New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLeuprolide vs PE-22-28

Leuprolide vs PE-22-28

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Leuprolide
Cognitive Enhancement
PE-22-28
Summary
Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
Half-Life
~3 hours (SC/IM), but depot formulations last 1–12 months
Relatively short; CNS effects may persist due to neurogenic mechanisms
Admin Route
SubQ, IM
SubQ, Intranasal
Research
Typical Dose
7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
200–400 mcg
Frequency
Per depot schedule
Once daily
Key Benefits
  • Medical: reduces testosterone in prostate cancer
  • Medical: suppresses estrogen in endometriosis and uterine fibroids
  • Medical: delays precocious puberty
  • Research: testosterone rebound effect after short course
  • Transgender care: hormone suppression in adolescents
  • Research: hormonal re-sensitization protocols
  • Rapid-onset antidepressant effects (within 24 hours)
  • Promotes hippocampal neurogenesis
  • Improves cognitive performance and memory
  • Reduces anxiety and depressive behavior
  • Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
  • May help treatment-resistant depression
  • Neuroprotective effects
Side Effects
  • Hot flashes (with testosterone suppression)
  • Decreased libido and erectile dysfunction
  • Initial testosterone flare (first 1–2 weeks)
  • Bone density loss with long-term use
  • +3 more
  • Generally well tolerated in animal models
  • Limited human data available
  • Possible mild headache or transient mood changes at initiation
  • Injection site reactions (SC)
Stacks With